New transplant approach aims to beat blood cancer with fewer side effects
NCT ID NCT05417971
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 33 times
Summary
This study tests a stem cell transplant for people with blood cancers like leukemia or lymphoma. It uses a milder chemotherapy and radiation plan to prepare the body for a half-matched donor's stem cells. The goal is to see if this approach helps the new cells grow safely and controls the cancer long-term. About 20 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Caitlin Guzowski
RECRUITINGAtlanta, Georgia, 30342, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.